Patients With Vulvovaginal Candidiasis

Vulvovaginal Candidiasis Clinical Trial

— EPP-AFG-VVC  

Official title:

Randomized Clinical Trial of a Mucoadhesive Gel Containing EPP-AF in Patients Diagnosed With Vulvovaginal Candidiasis

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03024502
• Other study ID #: 03.12.0056.00
• Secondary ID: 2013/50496-2
• Status: Recruiting
• Phase: Phase 1/Phase 2
• Start date: January 30, 2018
• Est. completion date: June 2020

Study information

• Verified date: October 2018
• Source: University of Sao Paulo
• Contact: silvana ma quintana, phd
• Phone: 5516981459112
• Email: quintana[@]fmrp.usp.br
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The present study aims to evaluate the safety of two mucoadhesive gels containing a propolis standardized extract identified as EPP-AF, with 1 and 2% of propolis. The efficacy studies with both propolis gels will be performed in comparison with clotrimazole cream in patients presenting vulvovaginal candidiasis.

Description:

Vaginal candidiasis is the second infection of the genital tract after bacterial vaginosis. Up to 75% of women will have at least one episode in their lives, but the clinical manifestations can be very variable. Around 10 to 20% will be asymptomatic and 5 to 10% will have the recurrent candidiasis that means 4 or more episodes in a year. The predominant symptoms are pruritus in 89% and burning during urination and sexual intercourse in 66%. The therapeutic regimen for acute fungal infections by C. albicans should consider the intensity of the clinical symptoms, recurrence, patient preference for the route of administration and consequent adherence to treatment, presence of pregnancy and the possibility of side effects. In general, the schemes include anti-fungal substances of the azoles type. Intravaginal administration of drugs requires the development of formulations suited to the area and adherence to the treatment can be increased if mucoadhesive formulations are obtained which avoid discomfort and provide adequate release of the active compounds. In this sense, the present project had the objective of developing a mucoadhesive gel containing Propolis Standardized (EPP-AF®) for the treatment of vaginal candidiasis, especially since preclinical efficacy and safety data demonstrated the clinical potential of the product. So the present proposal aims at the clinical study evaluate the efficacy of two formulations with 1 and 2% of propolis in comparison with clotrimazole cream treatment (patients affected by Candidiasis) and also evaluate the safety of both propolis gels in healthy volunteers. The efficacy protocol of the test product in patients with vaginal candidiasis will be performed in an open-label, randomized, three-arm, clinical trial with active clotrimazole-based control. Patients will be recruited (T0) and evaluated at 10 and 30 days after initiation of treatment, and the primary outcome will be the clinical cure rate.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 90
• Est. completion date: June 2020
• Est. primary completion date: January 2020
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: 18 Years to 49 Years

Eligibility

Inclusion Criteria:

-Have performed the clinical and laboratory diagnosis of vulvovaginitis by Candida

Exclusion Criteria:

• cPatients with recurrent candidiasis;

• History of hepatic, renal, hematological, cardiovascular diseases and with decompensated diabetes mellitus (glycemia above 200) and obesity with BMI above 35);

• Diagnosis of vulvovaginitis by another agent;

• Make use of chronic antimicrobials (informed by the patient)

• Be pregnant

• Allergy to some component of medications given

Related Conditions & MeSH terms

• Candidiasis
• Candidiasis, Vulvovaginal
• Vulvovaginal Candidiasis

Intervention

Drug:
• EPP-AF Gel 1%
Administration intravaginal of EPP-AG Gel 1%, 1x/day, 7 days
• EPP-AF Gel 2%
Administration intravaginal of EPP-AG Gel 1%, 1x/day, 7 days
• Clotrimazole
Administration intravaginal of clotrimazol, 1x/day, 7 days

Locations

Country	Name	City	State
Brazil	Clinical Hospital of Sao Paulo University	Ribeirao Preto	Sao Paulo

Sponsors (1)

Lead Sponsor	Collaborator
University of Sao Paulo

Country where clinical trial is conducted

Brazil, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	clinical cure	Participants will be evaluated on the tenth day after insertion in the study (on the third day after the termination of the vaginal cream). The clinical cure will be evaluated by means of a questionnaire and specular examination. The possibilities will be: Candidacy Resolution; No resolution of candidiasis; The questionnaire will be: Pruritus: yes or no Burning: yes or no Dysuria: yes or no Edema of the genital area: yes or no Running: yes or no; The specular examination will evaluate: Presence of hyperemia: yes or no Edema of the genital area: yes or no Presence of cracks: yes or no Pathological vaginal contents: yes or no The positive response to any of the questions or signs / symptoms will be considered as clinical failure	10 days
Secondary	microbiology cure	Participants will be evaluated on the tenth day after insertion in the study (on the third day after the termination of the vaginal cream). The patient's clinical complaint will be evaluated and the specular examination will be performed. In this evaluation will be collected the following exams: Vaginal pH measurement: Normal 3.5 to 4.5 Abnormal> 4.5; Bacterioscopy with KOH10%: Normal: absence of pseudohifas or other pathogenic elements Abnormal: presence of pseudohifas; Culture for candida albicans: Normal: Negative Abnormal: positive; PCR for candida: Normal negative Abnormal: positive; The possibilities will be: Candidacy Resolution; No resolution of candidiasis It will be considered microbiological cure when all laboratory tests are considered normal	10 days